Alexion to Build Biologics Manufacturing Facility in Ireland
The company will invest €100 million in the expansion of its Athlone facility.
In July 2016 Alexion Pharmaceuticals announced its plans to invest an additional €100 million (approximately $110.6 million) in the expansion of its Athlone, Ireland facility. The investment will include the addition of a new biologics manufacturing facility and create 50 additional jobs in Athlone, the company said in a press release. According to the company, the Athlone location currently houses a vial fill-finish facility.
Alexion is also constructing a large-scale bulk biologics manufacturing facility at its Dublin site in College Park. Between its facilities in Athlone and College Park, Alexion currently employs more than 250 people in Ireland, and expects to continue to grow to almost 500 employees by the end of 2019. Alexion has invested €600 million (approximately $663.82 million) in Ireland since 2014, the company noted.
Source: Alexion Pharmaceuticals
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
